This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / EpiWatch App Detects Seizures Accurately
Tech medical breakthrough

EpiWatch App Detects Seizures Accurately

Analysis based on 8 articles · First reported May 27, 2026 · Last updated Jun 04, 2026

Sentiment
70
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The successful Phase III trial and FDA clearance of the EpiWatch app, which runs on the Apple Inc., is expected to positively impact the medical device and technology sectors. This innovation could lead to increased demand for smartwatches with advanced health monitoring capabilities and open new revenue streams for companies like EpiWatch.

Healthcare Technology Medical Devices
Event Summary

A new study published in Neurology Open Access, an official journal of the American Academy of Neurology, found that the EpiWatch smartwatch app accurately detected tonic-clonic seizures with a low rate of false alarms. The study, led in part by James W. Wheless of Le Bonheur Children s Hospital, involved 242 adults and children with epilepsy monitored in a hospital setting. The app detected 46 out of 47 tonic-clonic seizures, achieving a 98% sensitivity, and had a false alarm rate 90% lower than other devices. The United States — Food and Drug Administration has cleared the EpiWatch app for marketing. This development, which utilizes the Apple Inc. platform, is significant for improving epilepsy management, reducing the risk of sudden unexpected death in epilepsy (SUDEP), and encouraging consistent use due to its discreet nature.

Entities Involved
oth
EpiWatch
EpiWatch developed the EpiWatch app, which has shown high accuracy in detecting tonic-clonic seizures, leading to its FDA clearance and potential for widespread adoption. This event significantly boosts the company's market position and product credibility.
Importance 100.0 Sentiment 80.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration cleared the EpiWatch app for marketing, providing regulatory approval that validates its safety and effectiveness. This clearance is crucial for the app's commercialization and adoption in healthcare.
Importance 80.0 Sentiment 50.0
per
James W. Wheless
James W. Wheless is a study author and director at Le Bonheur Children s Hospital, providing expert commentary and leadership in the research of the EpiWatch app. His involvement lends significant medical authority to the study's findings.
Importance 70.0 Sentiment 60.0
stock
Apple Inc.
The EpiWatch app operates on the Apple Inc., enhancing the device's utility and potentially increasing its market appeal to individuals with epilepsy and their caregivers. This expands the use cases for the Apple Inc. beyond general fitness and communication.
Importance 70.0 Sentiment 30.0
ngo
American Academy of Neurology
The American Academy of Neurology published the study in its journal, Neurology Open Access, and endorses advances that improve diagnostic accuracy and patient quality of life. This provides scientific credibility and dissemination for the EpiWatch app's findings.
Importance 60.0 Sentiment 40.0
oth
Le Bonheur Children s Hospital
Le Bonheur Children s Hospital is where James W. Wheless works and contributed to the study, highlighting its role in advanced medical research and epilepsy care.
Importance 50.0 Sentiment 40.0
Relationships
United States — Food and Drug Administration related ↔ Apple Inc.
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.